靶向叶酸受体α的抗体偶联药物研究进展  

Research advance of antibody-drug conjugates targeting folate receptor alpha

作　　者：李婷 Li Ting(No.1 Research Laboratory,Shanghai Institute of Biological Products Co.,Ltd.,Shanghai 200051,China)

机构地区：[1]上海生物制品研究所有限责任公司第一研究室,上海200051

出　　处：《国际生物制品学杂志》2023年第4期235-240,共6页International Journal of Biologicals

摘　　要：叶酸受体α(folate receptorα,FRα)是通过糖基磷脂酰肌醇链接的细胞表面糖蛋白,它在正常组织中的表达极度受限,而在包括卵巢癌、肺癌和乳腺癌在内的一系列实体肿瘤中过表达。FRα在肿瘤中的异常表达以及介导大分子复合物内化的能力,吸引了针对该靶点的抗体偶联药物(antibody-drug conjugate,ADC)的开发。此文对FRα在肿瘤学中的意义以及靶向FRα的ADC临床前和临床试验结果进行概述。Folate receptorα(FRα)is a cell surface glycoprotein linked by glycosyl-phosphatidylinositol.The expression of FRαin normal tissues is extremely limited,but it is overexpressed in a series of solid tumors including ovarian cancer,lung cancer and breast cancer.The abnormal expression of FRαin tumors and its ability to mediate internalization of macromolecular complexes attract the development of antibody-drug conjugate(ADC)for this target.In this review,the significance of FRαin oncology and the preclinical and clinical trials results of ADC targeting FRαare summarized.

关 键 词：叶酸受体Α 肿瘤 抗体偶联药物 

分 类 号：R979.1[医药卫生—药品]